Patents by Inventor Gideon Pilarski

Gideon Pilarski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pregabalin free of lactam and a process for preparation thereof
    Publication number: 20060281816
    Abstract: The present invention encompasses Pregabalin substantially free of Lactam and a process for obtaining Pregabalin substantially free of Lactam comprising extracting an acidic mixture containing a complex of Pregabalin with a strong mineral acid, with a C3-8 alcohol; and combining the organic phase with an organic base.
    Type: Application
    Filed: April 11, 2006
    Publication date: December 14, 2006
    Inventors: Lilach Hedvati, Gideon Pilarski, Yuriy Raizi, Sharon Tomer, Ziv Dee-Noor, Claude Singer
  • Pregabalin free of isobutylglutaric acid and a process for preparation thereof
    Publication number: 20060276544
    Abstract: A Pregabalin having a low level of 3-isobutylglutaric acid is provided.
    Type: Application
    Filed: May 10, 2006
    Publication date: December 7, 2006
    Inventors: Lilach Hedvati, Ziv Dee-Noor, Claude Singer, Gideon Pilarski, Yuriy Raizi, Sharon Tomer
  • Substantially pure cilostazol and processes for making same
    Patent number: 7067669
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: June 27, 2006
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Substantially pure cilostazol and processes for making same
    Patent number: 7064208
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: June 20, 2006
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Substantially pure cilostazol and processing for making same
    Patent number: 7060833
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: June 13, 2006
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Stable gabapentin having pH within a controlled range
    Publication number: 20060122271
    Abstract: A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3.
    Type: Application
    Filed: January 20, 2006
    Publication date: June 8, 2006
    Inventors: Claude Singer, Gideon Pilarski, Michael Pesachovich, Eduard Schwartz
  • Substantially pure cilostazol and processes for making same
    Publication number: 20060094757
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Application
    Filed: December 14, 2005
    Publication date: May 4, 2006
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Substantially pure cilostazol and processes for making same
    Publication number: 20060094756
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Application
    Filed: December 14, 2005
    Publication date: May 4, 2006
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Preparation of paroxetine involving novel intermediates
    Publication number: 20050277669
    Abstract: Disclosed are processes for preparing novel carbamate intermediates of paroxetine comprising dealkylating N-alkylparoxetine by reaction thereof with a haloalkyl ester of a haloformic acid, in a suitable organic solvent. Also disclosed are processes for preparing paroxetine comprising hydrolyzing the novel carbamate intermediates in a suitable solvent. Paroxetine prepared by the above processes can be neutralized with hydrogen chloride and crystallized as paroxetine hydrochloride anhydrous, hemihydrate or as a solvate of isopropanol. The invention is further directed to the novel carbamate intermediates formed by the disclosed processes.
    Type: Application
    Filed: August 17, 2005
    Publication date: December 15, 2005
    Inventors: Gideon Pilarski, Ilya Avrutov
  • Preparation of paroxetine involving novel intermediates
    Patent number: 6956121
    Abstract: Disclosed are processes for preparing novel carbamate intermediates of paroxetine comprising dealkylating N-alkylparoxetine by reaction thereof with a haloalkyl ester of a haloformic acid, in a suitable organic solvent. Also disclosed are processes for preparing paroxetine comprising hydrolyzing the novel carbamate intermediates in a suitable solvent. Paroxetine prepared by the above processes can be neutralized with hydrogen chloride and crystallized as paroxetine hydrochloride anhydrous, hemihydrate or as a solvate of isopropanol. The invention is further directed to the novel carbamate intermediates formed by the disclosed processes.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: October 18, 2005
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Gideon Pilarski, Ilya Avrutov
  • Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
    Patent number: 6936720
    Abstract: The present invention relates to a process of preparing benzisoxazole methane sulfonic acid-chloride (BOS—Cl) as an zonisamide intermediate via chlorination of benzisoxazole methane sulfonate. The present invention also discloses a process of preparing zonisamide via amidation of BOS—Cl. More particularly, the present invention provides a process of preparing zonisamide, comprising the steps of: a) chlorinating BOS, salts or esters thereof, with SOCl2 in an organic solvent and/or in the presence of a catalyst to form BOS—Cl; and b) amidating BOS—Cl in the presence of ammonia selected from the group consisting of aqueous ammonia in a biphasic system, masked ammonia and dry ammonia to form zonisamide.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: August 30, 2005
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Marioara Mendelovici, Neomi Gershon, Tamar Nidam, Gideon Pilarski, Greta Sterinbaum
  • Novel synthesis of gatifloxacin
    Publication number: 20050080264
    Abstract: Provided are a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.
    Type: Application
    Filed: August 14, 2003
    Publication date: April 14, 2005
    Inventors: Valerie Niddam-Hildesheim, Ben-Zion Dolitzky, Gideon Pilarski, Greta Sterimbaum
  • Substantially pure cilostazol and processing for making same
    Publication number: 20050065343
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Application
    Filed: September 27, 2004
    Publication date: March 24, 2005
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Substantially pure cilostazol and processes for making same
    Patent number: 6825214
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: November 30, 2004
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Stable gabapentin having pH within a controlled range
    Publication number: 20040147607
    Abstract: A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3.
    Type: Application
    Filed: January 16, 2004
    Publication date: July 29, 2004
    Inventors: Claude Singer, Gideon Pilarski, Michael Pesachovich, Eduard Schwartz
  • Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
    Publication number: 20040014983
    Abstract: The present invention relates to a process of preparing benzisoxazole methane sulfonic acid-chloride (BOS-Cl) as an zonisamide intermediate via chlorination of benzisoxazole methane sulfonate. The present invention also disloses a process of preparing zonisamide via amidation of BOS-Cl. More particularly, the present invention provides a process of preparing zonisamide, comprising the steps of: a) chlorinating BOS, salts or esters thereof, with SOCl2 in an organic solvent and/or in the presence of a catalyst to form BOS-Cl; and b) amidating BOS-Cl in the presence of ammonia selected from the group consisting of aqueous ammonia in a biphasic system, masked ammonia and dry ammonia to form zonisamide.
    Type: Application
    Filed: February 24, 2003
    Publication date: January 22, 2004
    Inventors: Marioara Mendelovici, Neomi Gershon, Tamar Nidam, Gideon Pilarski, Greta Sterinbaum
  • Preparation of paroxetine involving novel intermediates
    Publication number: 20030166938
    Abstract: Disclosed are processes for preparing novel carbamate intermediates of paroxetine comprising dealkylating N-alkylparoxetine by reaction thereof with a haloalkyl ester of a haloformic acid, in a suitable organic solvent. Also disclosed are processes for preparing paroxetine comprising hydrolyzing the novel carbamate intermediates in a suitable solvent. Paroxetine prepared by the above processes can be neutralized with hydrogen chloride and crystallized as paroxetine hydrochloride anhydrous, hemihydrate or as a solvate of isopropanol. The invention is further directed to the novel carbamate intermediates formed by the disclosed processes.
    Type: Application
    Filed: May 1, 2002
    Publication date: September 4, 2003
    Inventors: Gideon Pilarski, Ilya Avrutov
  • Substantially pure cilostazol and processes for making same
    Publication number: 20030166937
    Abstract: The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.
    Type: Application
    Filed: January 6, 2003
    Publication date: September 4, 2003
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Stable gabapentin having pH within a controlled range
    Publication number: 20030055109
    Abstract: A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3.
    Type: Application
    Filed: August 26, 2002
    Publication date: March 20, 2003
    Inventors: Claude Singer, Gideon Pilarski, Michael Pesachovich
  • Stable gabapentin containing more than 20 ppm of chlorine ion
    Patent number: 6531509
    Abstract: Pharmaceutical compositions containing substantially pure and stable gabapentin are disclosed wherein gabapentin contains an anion of a mineral acid, such as chloride, in amounts greater than 20 ppm.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: March 11, 2003
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Claude Singer, Gideon Pilarski, Michael Pesachovich, Edward Schwartz